What makes it easier for Knuth is the set-it-and-forget-it CNCs that run its roster of electric benders: the original 150-mm ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by ...

Endomines Finland Plc - inside information - 15.10.2025 at 12:30 Inside Information: Endomines Reports High-Grade Gold Intercepts at Hosko Endomines Finland Oyj has completed the drilling program carr ...

Vanadiferous titanomagnetite (“VTM”) mineralization at Radar is comparable to global Fe–Ti–V systems such as Panzhihua (China ...

A home isn’t just made of walls and a roof; it’s built from memories, habits, and the everyday objects that fill its spaces.

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib ...

Two nurses —Kyle Smith and Joanie Ippolito, who has since retired — founded Patches in 2000. Helping parents deal with the plight of their severely sick children —in some cases, with terminal ...

October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (CSPC) (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

Adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improved PFS in patients with platinum-resistant, recurrent ovarian cancer in a phase 3 trial.